Isolated brachioradialis metastasis of gastric adenocarcinoma after R0 resection

Elizabeth Jacob, Levi Smucker*, Ryan Crouse and Ayana Allard-Picou

Abstract
Background: Gastric cancer is the fifth most common cancer worldwide, with an incidence of 6.72 per 100,000 people. Thirty-two percent of gastric cancer patients will live 5 years after diagnosis. Single-site metastasis is noted in 26% of patients with gastric cancer, most commonly in the liver (48%), peritoneum (32%), lung (15%), and bone (12%). Here, a case is presented in which a single skeletal muscle metastasis appeared after appropriate resection and treatment.

Case presentation: A 63-year-old man underwent neoadjuvant chemotherapy and a multivisceral en bloc R0 resection. Final pathology showed no evidence of lymph node metastasis with 31 negative lymph nodes. Four months postoperatively, the patient was found to have a rapidly growing biopsy-proven extremity soft tissue gastric metastasis within the brachioradialis muscle. He subsequently underwent metastasectomy and immunotherapy.

Conclusion: This case is a rare example of an isolated extremity metastasis of gastric adenocarcinoma in the setting of an R0 resection of the primary tumor and negative nodal disease on final pathology, suggestive of hematogenous spread. We review the biology, workup, and management of gastric cancer and highlight new advancements in the treatment of this aggressive cancer.

Keywords: Gastric cancer, Metastatic cancer, Tumor biology, D2 lymphadenectomy
skeletal muscle metastasis. The case highlights a rare example of a skeletal muscle metastasis of gastric cancer, which occurs in 0.03 to 0.16%. A literature review notes at least 34 cases of reported skeletal metastases, occurring in very diverse areas of the body (Table 1). This rare case is particularly notable because it occurred in the setting of a histologically margin-negative (R0) resection and negative lymph nodes on final pathology [37]. The case also provides narrative of the oncologic and surgical management of gastric cancer, with review of prognostic factors.

**Case presentation**

The patient is a 63-year-old man with a history of smoking, COPD, and stage 1 urothelial cancer who presented with a 3-month history of epigastric abdominal pain, early satiety, fatigue, and 12-pound weight loss. Esophagogastroduodenoscopy (EGD) demonstrated a large posterior body gastric ulcer (Fig. 1), and biopsies revealed poorly differentiated adenocarcinoma based on microscopic features. Differential included metastatic urothelial cancer versus a more likely primary gastric cancer. Negative stains for CK20, PSA, PSAP, Uroplakin II, and other markers were negative.

**Table 1** Literature cases of skeletal metastases of gastric cancer

| Year | Authors | Age (years) | Sex | Affected muscles |
|------|---------|-------------|-----|-----------------|
| 1962 | Sato et al. [6] | N/A | N/A | Iliopsoas m. |
| 1979 | Treves and Barruch [7] | 52 | M | Psoas m. |
| 1983 | Obley et al. [8] | 54 | M | Paraspinal m. |
| 1983 | Fujiwara et al. [9] | 74 | F | NA |
| 1984 | Rosenbaum et al. [10] | 54 | M | Upper arm m., Femoral m. |
| 1989 | Arnold et al. [11] | 59 | F | Extraocular m. |
| 1990 | Porile et al. [12] | 65 | M | Sartorius m., Rectus femoris m. |
| 1993 | Sudo et al. [13] | 61 | M | Trapezius m. |
| 1993 | Fred et al. [14] | 47 | F | Extraocular m. |
| 1994 | Toillon et al. [15] | 58 | M | Gastrocnemius m. |
| 1996 | Armano and Kumazaki [16] | 57 | M | Gastrocnemius m. |
| 1997 | Ferri et al. [17] | N/A | N/A | Masseter m. |
| 1998 | Narvaez et al. [18] | 49 | M | Psoas m. |
| 1998 | Pestalozzi and von Hochstetter [19] | 72 | F | Gastrocnemius m. |
| 1998 | Pinto et al. [20] | N/A | N/A | NA |
| 2001 | Obi et al. [21] | 70 | M | Lumbar m., Iliopsoas m. |
| 2002 | Kondo et al. [22] | 64 | F | Gluteus maximus m., Adductor magnus m. |
| 2003 | Varma et al. [23] | 72 | M | Anterior femoral m. |
| 2004 | Tuoheti et al. [24] | 48 | M | Shoulder muscle. |
| 2004 | Tuoheti et al. [24] | 89 | M | Gluteal muscle. |
| 2006 | Bese et al. [25] | 60 | M | Paravertebral m. |
| 2008 | Souayah et al. [26] | 49 | M | Lateral rectus m. |
| 2009 | Toubon et al. [27] | 71 | M | Deltoid m. |
| 2011 | Sakurna et al. [28] | 64 | F | Gluteal m. |
| 2012 | Gogou et al. [29] | N/A | N/A | Femoral m. |
| 2014 | Pergolini et al. [30] | 67 | M | Adductor m. |
| 2014 | Lourenço et al. [31] | 68 | M | Upper thigh m. |
| 2015 | Koga et al. [32] | 71 | M | Multiple |
| 2016 | Xiao-Xia Wang [33] | 63 | M | N/A |
| 2016 | Ebisu [34] | 49 | F | Femoral mm. |
| 2017 | Termedo et al. [35] | 42 | M | Extraocular m. |
| 2018 | Kamitani et al. [36] | 47 | M | Latissimus dorsi m. |
| 2019 | Aguirre et al. [37] | 57 | F | Multiple |
| 2020 | Daneti et al. [38] | 42 | M | Psoas m., Gluteal mm. |
chromogranin, synaptophysin, CK7, and CD56, a weak GATA-3 stain and positive stains for AE1/AE3 confirmed a diagnosis of a new primary gastric cancer (Fig. 2). Endoscopic ultrasound revealed many abnormal lymph nodes in the celiac region (level 20), peripancreatic region, and porta hepatitis (largest measuring 9 mm by 5 mm) such that he was staged as a T3N3M0 by EUS criteria. PET scan revealed an FDG avid gastric mass. CT chest, abdomen, and pelvis and PET were negative for distant metastasis (Fig. 1). Given the presumptive clinical stage T3N3M0, staging laparoscopy with 1 L peritoneal lavage was performed. There was no evidence of any occult peritoneal metastasis at the time of surgery. However, washings were positive for extraluminal mucin, suggestive of a cytology positive lavage. He was presented at our multidisciplinary tumor board conference where the decision was made to proceed with neoadjuvant FLOT chemotherapy followed by restaging. He underwent four cycles of FLOT, followed by a restaging PET CT (positron emission tomography-computed tomography), which was negative for metastatic disease. A second staging laparoscopy with peritoneal washings was performed in the aforementioned fashion and lavage was negative for malignant cells, suggestive of conversion from cytology positive to cytology negative. Repeat EGD and CT imaging showed no significant changes in tumor size. Given the change in his cytological status, the patient was taken to the operating room for a planned gastrectomy, D2 lymphadenectomy, and placement of a feeding jejunostomy tube placement. On exploration of the abdomen, there was no evidence of diffuse metastatic disease. The tumor invaded through the posterior gastric wall and into the pancreatic body and transverse colon. An en bloc resection was performed which included a total gastrectomy, distal pancreatectomy, with splenectomy and transverse colon resection with end colostomy. A stapled Roux-en-Y esophagojejunostomy was constructed and a feeding jejunostomy tube was placed distal to this.
Pathology revealed an 8.3 cm, poorly differentiated adenocarcinoma with invasion into the pancreatic parenchyma and histologically negative margins. Thirty-one regional lymph nodes were negative for metastasis making his final stage ypT4b N0 M0, Stage III. His post-

![Fig. 1](image1.png) Initial endoscopic appearance of ulcerated mass in gastric fundus (a). Preoperative contrast-enhanced CT scan of the abdomen and pelvis (b). Yellow arrows demonstrate mass in gastric fundus and body

![Fig. 2](image2.png) Initial appearance of gastric cancer prior to treatment, staining negative for Uroplakin II and weak for GATA-3
operative course was uneventful. There was evidence of treatment effect related necrosis on final pathology indicating response to his neoadjuvant chemotherapy (Fig. 3).

According to NCCN guidelines, surveillance was planned with a history and physical exam every 3–6 months for the first 2 years, and every 6–12 months for the subsequent 3 years, and finally annually thereafter. Surveillance imaging was also planned according to NCCN guidelines with a contrast CT chest, abdomen, and pelvis every 6–12 months for the first 2 years and then annually for 5 years [39]. Approximately 3 months after surgery, the patient developed a rapidly enlarging right lateral forearm mass. MRI revealed a 7-cm heterogeneously enhancing intramuscular mass within the brachioradialis muscle. This mass was found to be FDG avid on PET (SUV 12) and several right axillary lymph nodes were noted to have mild uptake with SUV 2.9 (Fig. 4). Core biopsy revealed poorly differentiated adenocarcinoma, consistent with metastasis from his gastric primary. We discussed with the patient that resection of this mass would not improve his survival and that extremity metastasis has shown to be a poor prognostic sign in the literature [37]. Next generation sequencing was performed on this extremity metastasis, which included a gene profile of at least 500 genes. This was positive for PDL1, suggesting a benefit from immunotherapy. Positive PDL1 was defined by a Combined Positive Score, which is calculated by the number of PDL1 staining cells divided by the total viable tumor cells multiplied by 100. Somatic mutations were also noted in MSH2, MSH6, and PDL1 and were negative in HER2. However, genetic testing revealed no germline mutations such that a diagnosis of Lynch syndrome was not supported. Our recommendation was to initiate systemic therapy with a PDL1 inhibitor (pembroluzimab) prior to resection of this metastasis as a means to evaluate the tumor response to treatment. However, the patient strongly desired upfront resection of the tumor as it was symptomatic, so a successful metastasectomy was performed. Surveillance was continued with a thorough physical examination and PET scan every 3 to 6 months. Surveillance PET scans showed response to immunotherapy with resolution of the FDG avidity in his right axilla, as well as a decrease in the size of the previously FDG avid right axillary node (Fig. 5). EGD performed at 11 months following initial resection did not demonstrate any signs of local tumor recurrence at the esophagojejunostomy anastomosis (Fig. 6). The patient remains disease free at the time of this publication, 20 months from the time of diagnosis and 1 year after the diagnosis of metastatic disease.

Discussion and conclusions

The incidence of gastric cancer in the United States is 6.72 per 100,000 people, but it remains one of the cancers with the highest mortality. Of those that present with metastasis, the median survival is only three months [3]. Workup typically includes a thorough history and physical exam, EGD and EUS to determine the depth of invasion and evaluate regional lymph nodes, and staging chest/abdomen/pelvic CT with oral and IV contrast. A nutritional assessment is also recommended [39].

The Lauren classification divides gastric adenocarcinoma into intestinal, diffuse (signet ring), and intermediate types. Intestinal type gastric cancer has been shown to have a better 5-year overall survival than diffuse type and mixed type [40]. Gastric cancer is also characterized by the presence of somatic mutations, which develop as the tumor replicates and grows, as well as germline mutations. CDH1 mutations have now been identified in 64% of diffuse types of gastric cancer [41]. CDH1 codes

Fig. 3 H&E stain showing gastric tumor with necrosis, indicating response to neoadjuvant chemoradiotherapy. a Necrotic tumor as evidence of neoadjuvant treatment effect. b Viable tumor
for the E-cadherin, a cell surface protein important in maintaining intercellular connections. Thus, in those with documented CDH1 mutations, a prophylactic total gastrectomy after age 20 may be considered. In patients with diffuse type gastric cancer who do not have CDH1 mutations, germline mutations in PALB2, BRCA1, and RAD51C have been noted [42]. Mutations noted in intestinal-type gastric cancers include TP53, TP73, APC (adenomatous polyposis coli), TFF (trefoil factor family), DCC (deleted in colon cancer), and FHIT (fragile histidine triad) [43–49]. These mutations often affect a given patient’s response to chemotherapy [41]. Of note, the presented patient was positive for mutations in EBV (Epstein-Barr virus), which is typically associated with a favorable prognosis [50].

In the past, the role of perioperative chemotherapy in the management of gastric cancer was of significant focus. This initially entailed perioperative epirubicin, cisplatin, and continuous infusion of 5-flourouracil (ECF) as demonstrated in the seminal MAGIC trial [51], and was later replaced by the perioperative regimen of 5-flourouracil, leucovorin, oxaliplatin, docetaxel (FLOT) due to the improvement in overall survival in those
undergoing FLOT [52]. Recently, however, the discovery of targetable mutations unique to a given tumor’s biology has guided chemotherapeutic and immunotherapeutic options. These mutations include PDL-1 as studied in the KEYNOTE trial [53], microsatellite instability (MSI) which appears to predict higher response rate to PDL-1 blocking immunotherapies [54], and HER2 expression against which Trastuzumab can offer benefit [55]. Per national guidelines, immunotherapy is recommended in those with such targetable mutations who have unresectable locally advanced, recurrent or metastatic disease [39]. Our patient expressed both PD-L1 and MSI-H such that postoperative pembrolizumab was initiated with good response. Notably, he also had somatic mutations in MSH2, MSH6, and PDL1 which were expressed in the tumor, but germline testing revealed no such mutations. One limitation of our case report is that NGS testing was performed on the skeletal metastasis and not the primary gastric cancer, so it is difficult to say whether these mutations were present in the primary tumor.

Surgery is the only curative option for gastric cancer patients without metastatic disease. Since CT imaging determines metastatic disease approximately 81% of the time, recent practice guidelines have advocated diagnostic laparoscopy with peritoneal washing to detect metastatic disease in those with cT3 and/or cN+ disease and to help detect occult peritoneal metastases guide management in higher risk patients, particularly when a neoadjuvant course is pursued [56]. For those undergoing washings, cytology positivity is often the strongest predictor gastric-cancer related death on multivariate analysis [57]. However, positive cytology—as in this case report—is also an opportunity to assess chemotherapy response and candidacy for resection. A study of 1241 patients at Memorial Sloan Kettering revealed 93 patients with occult peritoneal metastasis. This study identified a subset of these patients (29%) with improved disease specific survival who were converted from positive to negative cytology [58]. Another trial, in Japan, demonstrated a three-year survival of 76% for this same specific subset of patients who undergo gastrectomy after successful positive-to-negative conversion by neoadjuvant therapy [59]. At the time of curative-intent gastrectomy, the literature clearly favors a more extensive nodal harvest to include hepatic, left gastric, celiac, and splenic arterial lymph nodes as part of what is known as a D2 lymphadenectomy [60]. Clinical trials have demonstrated lower locoregional recurrence and lower gastric-cancer-related death rates in patients who underwent D2 lymphadenectomy than patients who underwent D1 lymphadenectomy [61]. It should be noted that D3 lymphadenectomy is performed in Western societies less frequently than D2 lymphadenectomy owing to the increased morbidity of these extensive D3 nodal dissections with limited benefit in overall survival. Many Western randomized trials have failed to demonstrate a survival advantage with extended nodal dissection and D2 lymphadenectomy is considered to be the standard approach [62]. An adequate lymph node yield for appropriate staging in gastric cancer is considered to be at least 15 nodes, however, multiple studies have demonstrated that higher LN yield may be associated with improved surgical quality and improved overall survival in patients with gastric cancer [63]. At the time of surgery, this patient did not have abnormal portal lymph nodes and decision was made to perform a D2 lymphadenectomy. This operation resulted in a good lymph node yield with 31 nodes, none of which demonstrated any evidence of metastatic disease.

Disease-free survival is related to the adequacy of surgical resection and it is crucial to obtain an R0 resection to decrease rates of local recurrence. Gastric cancerspecific survival 5 years after an R0 resection has been shown to be 50%, while it is only 13–29% with an R1 resection [64–66].

Metastasectomy in gastric cancer is controversial. While some Japanese literature has reported increased survival after radical hepatic resection, this has not been consistently reproducible in other populations [67]. There are multiple pathways of gastric cancer dissemination in metastatic disease: lymphatic dissemination (74–88%), subperitoneal dissemination along the peri-gastric ligaments, mesentry, or omentum, direct invasion into adjacent organs (i.e., esophagus 60%), transperitoneal seeding (53%), and hematogenous dissemination (i.e., as seen in the rate of hepatic metastases) [68]. Though metastasectomy in gastric cancer has not been shown to improve overall survival, it may be considered as a reasonable palliative option if the patient is symptomatic and if it does not increase patient morbidity, as was the case in this patient.

Only 30 cases of skeletal muscle metastasis after a primary gastric cancer have been reported in the literature since 1960, and skeletal muscle metastasis portends an extremely poor prognosis [37]. This unique case report presents a patient with moderate response to neoadjuvant chemotherapy such that he ultimately underwent an R0 resection, but subsequently developed an isolated skeletal metastasis.

This report highlights that while gastric cancer remains a highly aggressive cancer, survival has significantly improved with neoadjuvant therapy, improvements in surgical technique and the advent of targeted therapies.

**Abbreviations**

R0: Microscopically margin-negative resection; D2: Lymphadenectomy harvesting hepatic, left gastric, celiac, and splenic arterial lymph nodes; SEER: Surveillance, Epidemiology and End Results; FLOT: 5-Flourouracil, leucovorin, oxaliplatin, docetaxel; EGD: Esophagogastroduodenoscopy;
EUS: Endoscopic ultrasound, PET-CT: Positron emission tomography-computed tomography, NCCN: National Comprehensive Cancer Network; MRI: Magnetic resonance imaging; FDG: Fluorodeoxyglucose; NGS: Next generation sequencing; MSI: Microsatellite instability

Acknowledgements
Dr. Timothy Chapman MD and Dr. Daniel Schreiber MD, Department of Pathology, Bassett Medical Center, Cooperstown, NY, United States. Dr. James Leonardo MD, Department of Medical Oncology, Bassett Medical Center, Cooperstown, NY, United States.

Authors’ contributions
EJ was involved in manuscript composition, primary research, and referencing. LS was involved in manuscript composition, primary research, and referencing. RC was involved in the compilation of pathology slides, imaging, and primary research and referencing. AAP was involved in manuscript composition, primary research, oversite, editing, verification, and guidance. The author(s) read and approved the final manuscript.

Funding
Funding for publication is through Bassett Research Institute, which is under the non-profit hospital network with whom the authors are associated. There are no private or industry funding sources.

Availability of data and materials
Not applicable.

Declarations

Ethics approval and consent to participate
Consent to participate was obtained in-person from the patient on May 18, 2020.

Consent for publication
Consent for publication was also obtained May 18, 2020.

Competing interests
The authors have no competing interests or financial interest in the publication as presented.

Author details
1Department of Surgery, Bassett Medical Center, Cooperstown, NY, USA.
2Columbia University College of Physicians and Surgeons, New York City, USA.

Received: 8 December 2020 Accepted: 9 March 2021
Published online: 20 March 2021

References
1. SEER Data (Surveillance E, and End Results). Cancer of the stomach. Cancer Statistics Review (1975-2014) [https://seer.cancer.gov/archive/csr/1975_2014/]. National Cancer Institute, DCCPS, Surveillance Research Program, updated April 2, 2018.
2. Maconi G, Maries G, Porro GB. Role of symptoms in diagnosis and outcome of gastric cancer. World J Gastroenterol. 2008;14(8):1149–55. https://doi.org/10.3748/wjg.v14.i8.1149.
3. Rihimaki M, Hemminki A, Sundquist K, Sundquist J, Hemminki K. Metastatic spread in patients with gastric cancer. Oncotarget. 2016;7(32):52307–16. https://doi.org/10.18632/oncotarget.10740.
4. Hu B, El Hajj N, Sittler S, Lammet N, Barnes R, Meloni-Ehrig A. Gastric cancer: classification, histology and application of molecular pathology. J Gastrointest Oncol. 2012;3(3):251–61. https://doi.org/10.3978/j.issn.2078-6891.2012.02.01.
5. Yang D, Hendifar A, Lenz C, Togawa K, Lenz F, Lurje G, Pohl A, Winder T, Ning Y, Grorsten S, Lenz HJ. Survival of metastatic gastric cancer: significance of age, sex and race/ethnicity. J Gastrointest Oncol. 2011;2(2):77–84. https://doi.org/10.3978/j.issn.2078-6891.2010.02.05.
6. Sato N, Saway Y, Fukumaki C. Case of stomach cancer with remote metastases to the entire body, especially to the spleen and bilateral ilioptas. Naika Intern Med. 1962;9:774–8.
carcinoma. Turk J Gastroenterol. 2012;23(5):611–2. https://doi.org/10.4318/tjg.2012.0394.

30. Pergolini I, Crippa S, Santinelli A, Marmore C. Skeletal muscle metastases as initial presentation of gastric carcinoma. Ann J Cancer Res. 2014;14(9):5580.

31. Lourenço LG, Carlotti JR, Herbelta FA, Silva DA, Setti HB. Muscular metastasis from gastric cancer. J Gastrointestinal Oncol. 2014;5(6):E100.

32. Koga Y, Baba Y, Hanada K, Kosumi K, Shigaki H, Kurahige J, Ishimoto T, Iwasuki M, Miyamoto Y, Sakamoto Y, Yoshida N. Multiple skeletal muscle metastases from poorly differentiated gastric adenocarcinoma. Surg Case Rep. 2015;1(1):1–5.

33. Wang XG, Liu HQ, Deng FR, Liu J. Skeletal muscle metastases as the first sign of a recurrence of gastric carcinoma. Dig Liver Dis. 2016;48(12):1515. https://doi.org/10.1016/j.dld.2016.08.003.

34. Ebisui C, Hamano R, Nusagawa Y, Garimasawa T, Okamura S, Fukuchi N, Murata K, Yokouchu K, Kinuta M, Ohishi K. A case of T1a early gastric cancer that metastasized to the right femoral muscles six years and seven months after radical surgery. Gan to kagaku ryoho Cancer Chemother. 2016;43(9):1893–5.

35. Ternido H, Vilao F, Parente F, Dipilipova as rare initial manifestation of gastric cancer. Acta Med Port. 2017;30(4):339.

36. Kamitani N, Watanabe A, Kihara7a Y, Ko S. Metachronous skeletal muscle metastasis without any other organ metastases after curative gastrectomy: a case report. Surg Case Rep. 2018;4(1):1–5.

37. Aguirre LE, Salcedo J, Zuquello R, Garcia-Buitrago M, Ardalán B. Metastatic involvement of skeletal muscle from gastric adenocarcinoma. Onc Med Case Rep. 2019;2019:1035780.

38. Danet D, Senthimithzhelan K, Verma SK, Mohan P. Gastric adenocarcinoma presenting with multiple skeletal muscle metastases. BMJ Case Rep. 2021;14(1):239518. https://doi.org/10.1136/bcr-2020-239518.

39. Ajanji JM, D’Amico TA, Bentrem DJ, Chao J, Corvera C, Das P, Denlinger C, Enzinger PC, Fanta R, Farah J, Gerdes H, Gibson M, Glowacki RE, Hochwald S, Hofstetter WL, Ilson DH, Johang KH, Keswani RN, Kleinberg LR, Klemmper S, Leong S, Ly GP, Matkovský KA, Mchamara M, Muczyk MF, Paluri RK, Park H, Perry KA, Pirmento G, Poustides GA, Rogers RE, Strong VE, Wiseman G, Willett CG, Yabouk D. National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology: gastric cancer; 2020.

40. Chen YC, Fang WL, Wang RF, Liu CA, Yang MH, Lo SS, Wu CW, Li AFY, Shyr YM, Huang HK. Clinicopathological variation of Lauren classification in gastric cancer. Pathol Oncol Res. 2021;25(2):197–202. https://doi.org/10.1007/s12053-021-00996-6.

41. Tan JB, Ivanova T, Lim KH, Ong CW, Deng N, Lee J, et al. Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology. 2011;141(2):476–85.e1–11.

42. Sahsabradude R, Pott L, Borghaei M, Toal T, Estrada AP, Suarez JJ, Brea-Amico TA, Bentrem DJ, Chao J, Corvera C, Das P, Denlinger C, Enzinger PC, Fanta R, Farah J, Gerdes H, Gibson M, Glowacki RE, Hochwald S, Hofstetter WL, Ilson DH, Johang KH, Keswani RN, Kleinberg LR, Klemmper S, Leong S, Ly GP, Matkovský KA, Mchamara M, Muczyk MF, Paluri RK, Park H, Perry KA, Pirmento G, Poustides GA, Rogers RE, Strong VE, Wiseman G, Willett CG, Yabouk D. National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology: gastric cancer; 2020.

43. Braga L, Mezzanotte M, Mocellin S, Pirastu G, Vaira D, Callea L, Bruni M, et al. Consensus on the role of p73 and related isoforms in the field of cancer biology and medicine: a European panel consensus of the p73 association network, 2019. Cancer Cell. 2020;37(2):233–51. https://doi.org/10.1016/j.ccell.2019.11.008.

44. Yang S, Liu J, Qiu X, Kong P, Chen S, Li W, Zhan Y, Li Y, Chen Y, Zhou Z, Xu D, Sun X. Prognostic significance of Epstein-Barr virus infection in gastric cancer: a meta-analysis. BMC Cancer. 2015;15(1):782. https://doi.org/10.1186/s12885-015-1813-9.

45. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20. https://doi.org/10.1056/NEJMoa055531.

46. Al-Batran SE, Homann N, Paulzik C, Goetze TD, Meller J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-esophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393(10184):1948–57. https://doi.org/10.1016/S0140-6736(18)32557-1.

47. Fuchs CS, Doi T, Iwagawa M, Kuroda T, Takahashi S, Ishiguro K, et al. Prognostic value of surgical margin status in gastric cancer patients. ANZ J Surg. 2015;85(11):931–6. https://doi.org/10.1111/ans.12515.

48. Shiao YH, Rugge M, Corea P, Lehmann HP, Scheer WD. p53 alteration in gastric precancerous lesions. Am J Pathol. 1994;144(3):511–7.

49. Tomkova K, Belkhiri A, El-Rifai W, Zaika AI. p73 isoforms can induce T-cell factor-dependent transcription in gastrointestinal cells. Cancer Res. 2004;64(18):6390–9. https://doi.org/10.1158/0008-5472.CAN-04-2176.

50. Liu X, Liu J, Qiu X, Kong P, Chen S, Li W, Zhan Y, Li Y, Chen Y, Zhou Z, Xu D, Sun X. Prognostic significance of Epstein-Barr virus infection in gastric cancer: a meta-analysis. BMC Cancer. 2015;15(1):782. https://doi.org/10.1186/s12885-015-1813-9.
67. Miyazaki M, Itoh H, Nakagawa K, Ambru S, Shimizu H, Togawa A, Shiobara M, Ohtsuka M, Sasada K, Shimizu Y, Yoshioka S, Nakajima N, Suwa T, Kimura F. Hepatic resection of liver metastases from gastric carcinoma. Am J Gastroenterol. 1997;92(3):490–3.

68. Young JJ, Pahwa A, Patel M, Jude CM, Nguyen M, Deshmukh M, Huang L, Mohammad SF. Ligaments and lymphatic pathways in gastric adenocarcinoma. Radiographics. 2019;39(3):668–89. https://doi.org/10.1148/rg.2019180113.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions